SMALL CELL LUNG CARCINOMA (SCLC)
Clinical trials for SMALL CELL LUNG CARCINOMA (SCLC) explained in plain language.
Never miss a new study
Get alerted when new SMALL CELL LUNG CARCINOMA (SCLC) trials appear
Sign up with your email to follow new studies for SMALL CELL LUNG CARCINOMA (SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weapon against tough lung cancer enters human testing
Disease control OngoingThis early-stage study aims to find a safe dose of an experimental drug called BI 764532 when given with standard chemotherapy. It is for adults whose extensive-stage small cell lung cancer has worsened after initial platinum-based treatment. The drug is designed to help the body…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Scientists test new Two-Pronged attack on Tough-to-Treat cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, obrixtamig and ezabenlimab, in adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest dose of the combination that p…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New weapon against aggressive lung cancer enters human testing
Disease control OngoingThis early-stage study is testing a new drug called BI 764532 (obrixtamig) when combined with standard chemotherapy and immunotherapy for extensive-stage small cell lung cancer. The main goal is to find the highest dose patients can safely tolerate. Researchers will also check if…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC